Quince Therapeutics, Inc.
$ 1.36
0.00%
24 Apr - close price
- Market Cap 22,169,100 USD
- Current Price $ 1.36
- High / Low $ 1.37 / 1.31
- Stock P/E N/A
- Book Value -6.41
- EPS -16.68
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -2.48 %
- 52 Week High 45.50
- 52 Week Low 0.80
About
Quince Therapeutics, Inc., a biopharmaceutical company, is focused on advancing precision therapies for rare and debilitating diseases. The company is headquartered in South San Francisco, California.
Analyst Target Price
$5.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-13 | 2025-08-11 | 2025-05-12 | 2025-03-31 | 2024-11-12 | 2024-08-13 | 2024-04-01 | 2024-02-14 | 2023-11-14 | 2023-08-03 | 2023-05-15 |
| Reported EPS | -0.4094 | -0.25 | -0.34 | -0.34 | -0.2839 | -0.1272 | -0.6434 | -0.2171 | -0.22 | -0.1483 | -0.136 | -0.3418 |
| Estimated EPS | -0.1833 | -0.22 | -0.26 | -0.23 | -0.1 | -0.1 | None | None | -0.28 | None | 0 | -0.3092 |
| Surprise | -0.2261 | -0.03 | -0.08 | -0.11 | -0.1839 | -0.0272 | 0 | 0 | 0.06 | 0 | -0.136 | -0.0326 |
| Surprise Percentage | -123.3497% | -13.6364% | -30.7692% | -47.8261% | -183.9% | -27.2% | None% | None% | 21.4286% | None% | None% | -10.5433% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QNCX
2026-04-24 00:39:41
Quince Therapeutics (Nasdaq:QNCX) is a biopharmaceutical company focusing on rare diseases, currently valued at US$22.2 million. The company faces significant risks including negative shareholder equity, low revenue, and substantial shareholder dilution, yet analysts project 67.24% earnings growth per year and a fair value suggesting it is undervalued. Recent news indicates delayed filings, Nasdaq non-compliance, and ongoing clinical trials for its lead asset, EryDex.
2026-04-23 22:09:26
Quince Therapeutics (QNCX) has appointed June Bray as an independent Class I director to its expanded four-member board, effective April 22, 2026, to serve until the 2026 annual meeting of stockholders. Bray will also serve on the Nominating & Governance, Audit, and Compensation committees. Spark, TipRanks’ AI Analyst, rates QNCX as Underperform due to weak financial performance and fragile technicals.
2026-04-23 17:09:26
Quince Therapeutics has reached an agreement to settle a $16.4 million debt for a payment of $5.5 million. This settlement significantly reduces the company's liabilities and could improve its financial standing. The move aims to optimize the company's financial structure and potentially free up resources for its core operations.
2026-04-22 21:38:51
Quince Therapeutics (QNCX) has expanded its board of directors to four members by appointing June Bray as an independent Class I director, effective immediately. Bray will serve on the Nominating & Governance, Audit, and Compensation committees and will receive standard cash retainers for her services. Despite an analyst rating on QNCX stock as a Buy with a $5.00 price target, TipRanks’ AI Analyst, Spark, rates QNCX as "Underperform" due to weak financial performance and high financing risk.
2026-04-22 20:38:51
Quince Therapeutics (NASDAQ:QNCX) has appointed June Bray as a Class I director to its board, expanding it to four members. Bray will serve on the Nominating & Governance, Audit, and Compensation Committees and receive standard non-employee director compensation. This appointment comes as the company navigates financial pressures, including a recent reverse stock split, debt settlement, Nasdaq compliance issues, and a failed clinical trial for its lead drug candidate.
2026-04-22 20:38:51
Quince Therapeutics, Inc. reported a material event in an 8-K filing, announcing that its Board of Directors increased its size to four members and appointed June Bray as an independent Class I director effective April 22, 2026. Ms. Bray will serve until the 2026 Annual Meeting of Stockholders and was appointed to the Nominating & Governance, Audit, and Compensation Committees. She will receive standard non-employee director compensation including annual retainers for Board and committee service.
